Background: endothelial activation is important in the pathogenesis of skin changes due to chronic venous disease (CVD).
Introduction
Pharmacological treatment is widely used to ameliorate the symptoms of venous disease in many EuroChronic venous disease (CVD) and its sequelae are a pean countries. It is hardly used in other places. One major cause of morbidity in the Western world. 1, 2 The reason for these discrepancies is the lack of controlled inflammatory response seen in CVD involves leucocyte scientific trials establishing the role of these comand endothelial adherence, cell activation and cell pounds. At least one recent study shows increased migration. This involves adhesion molecule expression ulcer healing rates in response to flavonoid treatment. 4 by endothelial cells, leucocyte activation and local Unfortunately, no "phlebotonic" drugs exist that claim cytokine activity. Currently there are no studies re-to correct venous valvular incompetence. However, garding the changes in these endothelial markers fol-many of these do affect the inflammatory changes lowing therapy for CVD.
responsible for the skin damage. Endothelial cell activation by cytokines or thrombin
The response of the increased endothelial activation leads to increased adhesion molecule expression. These to any form of therapy remains unknown. The medical include ICAM-1 (binds neutrophil/lymphocytes) and compounds that have been used for treating venous VCAM-1 (binds lymphocytes/monocytes). This can disease include flavonoids (diosmin/hydoxyethyllead to MHC-II (T-cell response) and GMP-140 (binds rutosides), methyl-xanthines, prostaglandin and fibplatelets) expression. Binding of platelets increases the rinolytics amongst others. A purified micronised flaavailability of platelet-activating factor and further vonoid fraction (Daflon∈500, Servier Laboratories, accelerates the expression of adhesion molecules. The France) has been used in Europe for the treatment of circulating levels of many of these molecules are CVD for some time. Daflon consists of 90% Diosmin (3′, known to be increased in patients with CVD. Fig. 1 . Chronic venous disease leads to a microangiopathy. This involves adhesion molecule expression by endothelial cells, leucocyte activation and local cytokine activity. Endothelial cell activation by cytokines or thrombin leads to increased adhesion molecule expression. This includes ICAM-1 (binds neutrophils/lymphocytes), VCAM-1 (binds lymphocytes/monocytes) and E-selectin (ELAM-1). MHC-II (Tcell response) and GMP-140 (binds platelets) expression can occur. Binding of platelets increases the availability of platelet-activating factor and further accelerates the expression of adhesion molecules. The circulating levels of many of these molecules are known to be increased in patients with CVD.
variable, mainly because of lack of good controlled soluble markers of endothelial activation in CVD. In addition plasma lactoferrin levels were studied as a trials. There is evidence of increased healing rate of venous ulcers with Daflon. 5 marker of neutrophil degranulation. 7 Daflon∈ comprises 450 mg of diosmin and 50 mg of hesperidin per tablet. The "micronisation" of the effective components increases its bio-availability. It has been reported to be a "venotonic" (increases venMaterials and Methods ous tone!) and to decrease capillary "leakage" in many scenarios. A double-blind randomised trial published Evaluation in 1994 had shown its efficacy in treating the clinical symptoms of CVD without any significant side-effects. 6 Ethics committees' consent for the study was obtained from UCL Medical School Committee for medical The aim of our study was to study the effects of micronised purified flavonoid fraction (S5682, Daflon∈ ethics. Patients with chronic venous disease, clinical stage 2-4, were recruited from the vascular clinic at 500 mg, Servier, France) treatment on expression of urea and electrolyte/liver function tests. All patients were assessed clinically according to the clinical classification of the Hawaii system. People with (duplex proven) varicose veins only (C2), with associated oedema (C3), skin changes (C4) and/or healed ulceration (C5) of >4 weeks were included. Active ulceration (C6) would have interfered with activation of leukocytes and these were thus not included.
All patients had a venous duplex examination and photoplethysmography within the previous 8 weeks to establish venous disease and to localise it anatomically. The minimum extent of duplex examination in our patients included saphenofemoral junction, long saphenous vein, saphenopopliteal junction, short saphenous vein, anatomical perforators. Femoropopliteal veins and other reflux sites as picked up by colour Doppler. Patients were assessed for other possible diagnoses, including arterial disease. Anklebrachial pressure ratios were performed whenever Patient selection the Middlesex Hospital. Patients who consented were asked to attend the department on three separate The inclusion criteria for the study were: (1) age above 18 years; (2) patients affected with Hawaii stage C2 to occasions at 2 weeks before treatment, the day of starting treatment and after finishing treatment. A C4; (3) C6 with a healed ulcer for at least 4 weeks, 8 (4) psychological stability and motivation. medical history was taken and clinical examination performed. This included a systemic as well as venous
The exclusion criteria were directed at: (i) patients who examination. Patients had a full blood count, serum (NSAIDs), other "vaso-active" drugs, Vitamins A, C and E or anticoagulants; (12) previous poor compliance to treatment; (13) participants of a trial within past 3 months were excluded; (14) pregnancy, breastfeeding or lack of active contraception also excluded the patient.
Daflon∈ 500 mg twice daily (Servier, France) was administered for 60 days. Evaluation of venous symptoms employing a visual analogue scale was performed before and after treatment. Specimens (30 ml each) were taken from foot veins before and after standing the patient supported for 30 min. The patient then stood supported against the side of Probability levels are Wilcoxon ranked-sum test. The much increased plasma lactoferrin activity is lowered significantly in patients with the couch for 30 min without moving the calf muscles skin changes.
Collection of specimens
(it was previously shown by the authors by direct pressure measurement that this raises the venous preshave conditions that would change the status of leu-sure in the superficial veins of the leg to between 70 kocyte/endothelial activation; (ii) subjects who were and 80 mmHg), after which 2 ml of blood was taken taking compounds similar to flavonoids to avoid bias and discarded from the cannula, and a further 10 ml and (iii) patients who had other major systemic ill-was collected into two tubes containing ethylenenesses. These criteria were: (1) history of alcohol or diamine <TK; 4 tetra-acetic acid and one tube condrug abuse; (2) known history of allergy or intolerance taining citrate <TK; 1 (Vacutainer Becton Dickinson to diosmin or any other venotonic agent; (3) active Vacutainer Systems Europe, BP No 37-38341 Meylan venous ulceration; (4) diabetes mellitus; (5) impaired Cedex, France). Blood samples were carefully placed hepatic function (ALT or AST 3-fold above the normal directly into the sample tubes after removing the limit) or impaired renal function (serum creatinine stoppers to prevent excessive cell agitation. >120 mol/l); (6) any concomitant active disease or abnormality in laboratory test (judged as clinically significant by the investigator); (7) patients treated with other vasoactive drugs within the 15 days prior ELISA tests for soluble markers to inclusion; (8) patients with an acute/chronic inflammatory or infectious disease; (9) deep venous Blood for ELISA tests for soluble plasma markers was collected in EDTA bottles. The specimens were spun thrombosis within the past 12 months; (10) superficial venous thrombosis within 3 weeks; (11) patients at 20,000 r.p.m. for 10 min to separate the plasma and promptly frozen at −20°C before analysis. The using steroids, non-specific anti-inflammatory drugs Markers measured were E-selectin, P-selectin, VCAM, monocytes and lymphocytes were decreased significantly. This effect was seen in all patients, ir-ICAM-1, VW factor and lactoferrin. Commercial kits were used for these tests (ICAM-1/VCAM/E-selectin respective of their clinical stage. Lactoferrin levels were appreciably reduced following therapy in patients with by R&D Systems, 4-10 The Quadrant, Barton Lane, Abingdon, Oxon OX14 3YS, U.K.; VW factor kit by skin changes only. This probably represents damping of the much-increased granulocyte activity in these Diagnostica Stago, 9 rue des Freres Chausson, 92600 Asnierès-sur-Seine, France; lactoferrin assay by OXIS patients compared to those with simple CVD. The effect on E-selectin levels was also seen more in the International, Portland, OR, U.S.A.) were used for these analyses.
C4 group. Unknown effects on platelet activity might explain the slight rise seen in P-selectin following therapy. Similar effects may explain the differing phenomena seen with VW factor following therapy (rise Demographics in VW factor in C3 patients and fall in C4 group). We did not make any distinction between patients There were equal numbers of patients with and withwith superficial venous insufficiency and those with out skin changes (n=10). Seven patients in each group deep venous insufficiency in interpreting the results. had superficial venous insufficiency (SVI). Of the rePrevious studies from this department did not report maining six patients the majority (5) had combined on any difference between these two groups 9 for a SVI and deep venous insufficiency (DVI). Most patients similar clinical stage. We compared equivalent clinical either had long saphenous (LSV) involvement (n=9) stages (C) which are representative of the severity of or combined LSV and short saphenous (SSV) in-CVD. Some of these markers, especially VW factors, are volvement (n=7). Two patients had CVD involving not very sensitive indicators of endothelial activation. neither of the two major superficial anatomic systems.
Some, like P-selectin and VW factor, are almost cerThese patients had other superficial veins (e.g. lateral tainly affected by other local phenomena like platelet superficial vein of the thigh) involvement without activation. The physiological significance of these solreflux in the mentioned major superficial systems.
uble markers remains an issue of debate. They may represent protease cleavage from cell surface subsequent to endothelial stimulation. They may also Results represent molecules released to block receptors and to prevent their attachment to the endothelium. Significant reduction was seen in plasma levels of It is only relatively recently that the effectiveness VCAM and ICAM-1 activity following therapy. Re-of therapy for CVD is being tested with objective duction in the level of ICAM-1 32% (141 ng/ml: 73 ng/ parameters. It has been shown that colour-duplex ml) and VCAM, 29% (1292 ng/ml: 717 ng/ml) were ultrasonographic and air-plethysmographic criteria seen. Reduction in plasma lactoferrin (36% decrease, improve in patients 1 month following surgical ther-760 ng/ml: 560 ng/ml) occurred in the skin-changes apy. This improvement was shown to be maintained group. The levels of VW factor also decreased in at 2 years.
10 It would be interesting to measure the patients with skin changes but not in simple venous mid to long-term effect of therapy on endothelial disease.
markers. Another study of the effect of compression Changes in E-selectin levels (decrease) and P-selectin therapy/scleropathy on the microangiopathy (Leu et levels (some increase following therapy) were not al.)
11 showed non-significant changes post-therapy. The significant statistically. The levels of reduction in endo-parameters studied were capillary microscopy, Dopthelial markers following flavonoid therapy was seen pler fluxmetry and tcPo 2 measurement. Elevated levels to be similar in each of the different supine-of VCAM-1, VW factor, E-selectin, IAM-1 and lacstanding-supine positions.
toferrin have been reported in patients with CVD compared to controls. 12 However, our study is the first to demonstrate a measurable change in these Discussion parameters in CVD following therapy. This shows the feasibility of using the soluble markers of endothelial We observed a decrease in some soluble endothelial activation as a parameter to measure the response to activation markers in patients with CVD following various forms of treatment. 60 d therapy with oral purified flavonoid fraction. In Experimental blockade of adhesion molecules either particular VCAM-1 and ICAM-1, adhesion molecules with soluble ligands or with specific monoclonal antibodies has a dramatic effect on inflammation and important in endothelial interaction with neutrophil, immune mediated tissue damage. 13 clinical course of CVD. The role of purified micronised
